In a recent study, it was found that patients in blast and accelerated phases displayed significantly lower levels of survivin-2B and -δEx3, compared to patients in CML-CP. This evidence concerns the gene BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive.